Multi-Specific Binding Proteins Targeting NKG2D and CD16
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are not effective for all patients and often have significant adverse side effects, and there is a need for more specific therapies that can effectively target and destroy cancer cells using the patient's immune system.
Innovation Solution
Development of multi-specific binding proteins that bind to the NKG2D receptor and CD16 on natural killer cells, as well as tumor-associated antigens such as EpCAM, CA125, NaPi2b, Nectin4, Fucosyl-GM1, ADAM8, ADAM9, SLC44A4, and CA19-9, to activate NK cells and facilitate the destruction of tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used, then cancer cells can be treated, but the treatments are not effective for all patients and have substantial adverse side effects
Solution Approach 1:
The patent creates multi-specific binding proteins that can bind to multiple different tumor-associated antigens simultaneously (e.g., EpCAM, CA125, Nectin-4, NaPi2b). This multi-functionality allows a single therapeutic agent to target various cancer types and antigen expressions, improving treatment effectiveness across different patients while maintaining specificity through targeted antigen recognition rather than systemic chemotherapy.
2Reliability
If multi-specific binding proteins are developed to target multiple antigens, then treatment effectiveness is improved, but the device complexity increases
Solution Approach 1:
The patent merges multiple antigen-binding specificities into a single binding protein molecule. The multi-specific binding protein is constructed by combining different binding domains (such as scFv or Fab fragments) that recognize different tumor-associated antigens within one molecular structure. This merging approach achieves the benefit of targeting multiple antigens while consolidating what could have been multiple separate therapies into a single agent.
Solution Approach 2:
The binding protein structure employs a nested organization where multiple binding domains are hierarchically arranged within the molecular framework. Each binding domain (targeting different antigens like EpCAM, CA125, Nectin-4) is nested within the overall protein structure, allowing compact organization of multiple functions. This nested architecture reduces the space and structural complexity required to accommodate multiple binding specificities.
3Adaptability or versatility
If conventional cancer therapies are used, then treatment can be administered, but they lack specificity and affect healthy cells
Solution Approach 1:
The multi-specific binding proteins exhibit local quality by concentrating their binding activity specifically at tumor cell surfaces where multiple antigens are co-expressed. The proteins are designed to recognize and bind to specific combinations of tumor-associated antigens (EpCAM, CA125, Nectin-4, NaPi2b) that are locally present on cancer cells but absent or minimally expressed on healthy cells. This localized specificity ensures that the therapeutic effect is concentrated at the tumor site while sparing healthy tissues.
Data Source
AI summary
Multi-specific binding proteins that bind the NKG2D receptor, CD16, and a tumor-associated antigen are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.